Compare · ABVX vs LLY
ABVX vs LLY
Side-by-side comparison of Abivax SA (ABVX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABVX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.20T, about 159.5x ABVX ($7.55B).
- Over the past year, ABVX is down 7.7% and LLY is up 56.0% - LLY leads by 63.6 points.
- LLY has hit the wire 22 times in the past 4 weeks while ABVX has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 17 for ABVX).
- Company
- Abivax SA
- Eli Lilly and Company
- Price
- $87.07+0.70%
- $1281.52+0.16%
- Market cap
- $7.55B
- $1.20T
- 1M return
- -10.05%
- +8.10%
- 1Y return
- -7.66%
- +55.98%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 0
- 22
- Recent ratings
- 17
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ABVX
- Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
- SEC Form F-6EF filed by Abivax SA
- SEC Form 6-K filed by Abivax SA
- Abivax Presents Business Updates and First Half 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA
- Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
- Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
- Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA
- Abivax Announces Closing of $920 Million Public Offering
- SEC Form 6-K filed by Abivax SA
Latest LLY
- Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- Lilly declares fourth-quarter 2026 dividend
- Gabelli To Host 8th Annual Healthcare Symposium
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
- SEC Form 3 filed by Eli Lilly and Company
- Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter
- Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
- SEC Form 4 filed by Eli Lilly and Company